Dual approach to ejaculatory control: daily paroxetine and on-demand lidocaine spray for treating premature ejaculation

Background: Premature ejaculation (PE) is a prevalent sexual dysfunction that affects a large number of men and can significantly impact their quality of life and intimate relationships. Current treatment options primarily include behavioral techniques and pharmacological interventions; however, the optimal therapeutic strategies remain unclear. This study aimed to evaluate the efficacy and safety of a combination treatment therapy using daily paroxetine 20 mg and on-demand lidocaine spray in men diagnosed with both erectile dysfunction and premature ejaculation. Methods: A cohort of men aged 18–65, diagnosed with PE and maintaining stable heterosexual relationships for over six months, received the proposed regimen. Results: The findings revealed a significant increase in intravaginal ejaculatory latency time (IELT) along with significant improvements in patient-reported outcomes, highlighting the potential of dual therapy to enhance sexual satisfaction. Conclusions: This single-arm study suggests that the combination of daily paroxetine and on-demand lidocaine spray may improve IELT and patient-reported outcomes in men with PE. However, the lack of a control group limits definitive conclusions. These preliminary findings support the need for future randomized controlled trials to validate the efficacy of this dual therapy compared to monotherapies or a placebo. Clinical Trial Registration: https://www.isrctn.com/ISRCTN31283266?q=ISRCTN31283266&filters=&sort=&off\set=1&totalResults=1&page=1&pageSize=10, ISRCTN31283266.

Premature ejaculation; Paroxetine; Lidocaine; Intravaginal ejaculation latency time

[1] Panahi R, Anbari M, Javanmardi E, Ghoozlu KJ, Dehghankar L. The effect of women’s sexual functioning on quality of their sexual life. Journal of Preventive Medicine and Hygiene. 2021; 62: E776–E781.

[2] Ziaei T, Keramat A, Kharaghani R, Haseli A, Ahmadnia E. Comparing the effect of extended PLISSIT model and group counseling on sexual function and satisfaction of pregnant women: a randomized clinical trial. Journal of Caring Sciences. 2022; 11: 7–14.

[3] World Health Organization. Sexual health. 2020. Available at: https://www.who.int/health-topics/sexual-health#tab=tab_1 (Accessed: 09 October 2024).

[4] Raveendran AV, Agarwal A. Premature ejaculation-current concepts in the management: a narrative review. International Journal of Reproductive BioMedicine. 2021; 19: 5–22.

[5] Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second international society for sexual medicine ad hoc committee for the definition of premature ejaculation. Sexual Medicine. 2014; 2: 41–59.

[6] Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The premature ejaculation prevalence and attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. European Urology. 2007; 51: 816–823; discussion 824.

[7] Serefoglu EC, Yaman O, Cayan S, Asci R, Orhan I, Usta MF, et al. Prevalence of the complaint of ejaculating prematurely and the four premature ejaculation syndromes: results from the Turkish Society of Andrology Sexual Health Survey. The Journal of Sexual Medicine. 2011; 8: 540–548.

[8] Karabakan M, Bozkurt A, Hirik E, Celebi B, Akdemir S, Guzel O, et al. The prevalence of premature ejaculation in young Turkish men. Andrologia. 2016; 48: 895–899.

[9] Gul M, Bocu K, Serefoglu EC. Current and emerging treatment options for premature ejaculation. Nature Reviews Urology. 2022; 19: 659–680.

[10] Gul M, Carvajal A, Serefoglu EC, Minhas S, Salonia A. European association of urology guidelines for sexual and reproductive health 2020: what is new? International Journal of Impotence Research. 2020; 32: 477–479.

[11] Sookaromdee P, Wiwanitkit V. Correspondence on: His452Tyr 5-HT2A polymorphism and intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. International Journal of Impotence Research. 2023; 35: 172.

[12] Cai T, Gallelli L, Verze P, Salonia A, Palmieri A. Prilocaine/lidocaine spray for the treatment of premature ejaculation: a dose- and time-finding study for clinical practice use. International Journal of Impotence Research. 2023; 35: 378–384.

[13] Symonds T, Perelman MA, Althof S, Giuliano F, Martin M, May K, et al. Development and validation of a premature ejaculation diagnostic tool. European Urology. 2007; 52: 565–573.

[14] Serefoglu EC, Yaman O, Cayan S, Asci R, Orhan I, Usta MF, et al. The comparison of premature ejaculation assessment questionnaires and their sensitivity for the four premature ejaculation syndromes: results from the Turkish society of andrology sexual health survey. The Journal of Sexual Medicine. 2011; 8: 1177–1185.

[15] Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, et al. Premature ejaculation: an observational study of men and their partners. The Journal of Sexual Medicine. 2005; 2: 358–367.

[16] Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49: 822–830.

[17] Turunc T, Deveci S, Güvel S, Peşkircioğlu L. The assessment of Turkish validation with 5 question version of International Index of Erectile Function (IIEF-5). Urology Research and Practice. 2007; 33: 45–49.

[18] Parnham A, Serefoglu EC. Classification and definition of premature ejaculation. Translational Andrology and Urology. 2016; 5: 416–423.

[19] Castiglione F, Albersen M, Hedlund P, Gratzke C, Salonia A, Giuliano F. Current pharmacological management of premature ejaculation: a systematic review and meta-analysis. European Urology. 2016; 69: 904–916.

[20] Lee HY, Pyun JH, Shim SR, Kim JH. Efficacy of various treatment in premature ejaculation: systematic review and network meta-analysis. World Journal of Men’s Health. 2024; 42: 338–346.

[21] Liu H, Zhang M, Huang M, Cai H, Zhang Y, Liu G, et al. Comparative efficacy and safety of drug treatment for premature ejaculation: a systemic review and Bayesian network meta-analysis. Andrologia. 2020; 52: e13806.

[22] Mirone V, Arcaniolo D, Rivas D, Bull S, Aquilina JW, Verze P; PAUSE study team. Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: the PAUSE study. European Urology. 2014; 65: 733–739.

[23] Tuken M, Culha MG, Serefoglu EC. Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction-DAP-SPEED Study. International Journal of Impotence Research. 2019; 31: 92–96.

[24] Gameel TA, Tawfik AM, Abou-Farha MO, Bastawisy MG, El-Bendary MA, El-Gamasy Ael-N. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology. 2013; 11: 392–397.

[25] Raisi F, Soleimani R, Ahmadzadeh A, Sadati SN, Fakhrian A, Jalali MM. Efficacy and safety of pharmacological treatments in patients with premature ejaculation: an umbrella review of meta-analyses of randomized controlled trials. The Journal of Sexual Medicine. 2025; 22: 1014–1023.

[26] Çeker G, Cinar O, Turunç T, Kızılkan Y, Anıl H, Akgün U, et al. Management and treatment variations in premature ejaculation: a nationwide survey by the andrology working group of the society of urological surgery in Turkey. International Urology and Nephrology. 2025; 57: 3655–3665.